Aligos Therapeutics Inc (ALGS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Sales | 1,269 | 1,061 | 986 | 2,681 | 3,239 |
| Gross Profit | 1,269 | 1,061 | 986 | 2,681 | 3,239 |
| Operating Expenses | 21,400 | 27,475 | 23,032 | 28,678 | 22,310 |
| Operating Income | -20,131 | -26,414 | -22,046 | -25,997 | -19,071 |
| Other Income | 963 | 31,664 | -12,793 | -1,925 | 1,059 |
| Pre-tax Income | -19,168 | 5,250 | -34,839 | -27,922 | -18,012 |
| Income Tax | 91 | 189 | 24 | -30 | 29 |
| Net Income Continuous | -19,259 | 5,061 | -34,863 | -27,892 | -18,041 |
| Net Income | $-19,259 | $5,061 | $-34,863 | $-27,892 | $-18,041 |
| EPS Basic Total Ops | -3.07 | 0.81 | -5.58 | 0.17 | -10.37 |
| EPS Basic Continuous Ops | -3.07 | 0.81 | -5.58 | 0.40 | -10.37 |
| EPS Diluted Total Ops | -3.07 | 0.81 | -5.58 | 0.17 | -10.37 |
| EPS Diluted Continuous Ops | -3.07 | 0.81 | -5.58 | 0.40 | -10.37 |
| EPS Diluted Before Non-Recurring Items | -3.07 | 0.75 | -5.50 | N/A | N/A |
| EBITDA(a) | $-19,939 | $-26,656 | $-21,456 | $-25,222 | $-18,390 |